RT Journal Article
SR Electronic
T1 Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020–May 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.06.22273409
DO 10.1101/2022.04.06.22273409
A1 Farrar, Daniel S.
A1 Drouin, Olivier
A1 Hepburn, Charlotte Moore
A1 Baerg, Krista
A1 Chan, Kevin
A1 Cyr, Claude
A1 Donner, Elizabeth J.
A1 Embree, Joanne E.
A1 Farrell, Catherine
A1 Forgie, Sarah
A1 Giroux, Ryan
A1 Kang, Kristopher T.
A1 King, Melanie
A1 Thibodeau, Melanie Laffin
A1 Orkin, Julia
A1 Ouldali, Naïm
A1 Papenburg, Jesse
A1 Pound, Catherine M.
A1 Price, Victoria E.
A1 Proulx-Gauthier, Jean-Philippe
A1 Purewal, Rupeena
A1 Ricci, Christina
A1 Sadarangani, Manish
A1 Salvadori, Marina I.
A1 Thibeault, Roseline
A1 Top, Karina A.
A1 Viel-Thériault, Isabelle
A1 Kakkar, Fatima
A1 Morris, Shaun K.
YR 2022
UL http://medrxiv.org/content/early/2022/04/07/2022.04.06.22273409.abstract
AB Background Children living with chronic comorbid conditions are at increased risk for severe COVID-19, though there is limited evidence regarding the risks associated with specific conditions and which children may benefit from targeted COVID-19 therapies. The objective of this study was to identify factors associated with severe disease among hospitalized children with COVID-19 in Canada.Methods We conducted a national prospective study on hospitalized children with microbiologically confirmed SARS-CoV-2 infection via the Canadian Paediatric Surveillance Program from April 2020–May 2021. Cases were reported voluntarily by a network of >2800 paediatricians. Hospitalizations were classified as COVID-19-related, incidental infection, or infection control/social admissions. Severe disease (among COVID-19-related hospitalizations only) was defined as disease requiring intensive care, ventilatory or hemodynamic support, select organ system complications, or death. Risk factors for severe disease were identified using multivariable Poisson regression, adjusting for age, sex, concomitant infections, and timing of hospitalization.Findings We identified 544 children hospitalized with SARS-CoV-2 infection, including 60·7% with COVID-19-related disease and 39·3% with incidental infection or infection control/social admissions. Among COVID-19-related hospitalizations (n=330), the median age was 1·9 years (IQR 0·1–13·3) and 43·0% had chronic comorbid conditions. Severe disease occurred in 29·7% of COVID-19-related hospitalizations (n=98/330), most frequently among children aged 2-4 years (48·7%) and 12-17 years (41·3%). Comorbid conditions associated with severe disease included technology dependence (adjusted risk ratio [aRR] 2·01, 95% confidence interval [CI] 1·37-2·95), neurologic conditions (e.g. epilepsy and select chromosomal/genetic conditions) (aRR 1·84, 95% CI 1·32-2·57), and pulmonary conditions (e.g. bronchopulmonary dysplasia and uncontrolled asthma) (aRR 1·63, 95% CI 1·12-2·39).Interpretation While severe outcomes were detected at all ages and among patients with and without comorbidities, neurologic and pulmonary conditions as well as technology dependence were associated with increased risk of severe COVID-19. These findings may help guide vaccination programs and prioritize targeted COVID-19 therapies for children.Funding Financial support for the CPSP was received from the Public Health Agency of Canada.Competing Interest StatementKrista Baerg has received royalties from Brush Education, and provided contracted services to the College of Medicine, University of Saskatchewan and Saskatchewan Health Authority - Saskatoon. She also served on the Board of Directors of the Saskatchewan Pain Society Inc., and as Saskatchewan Branch President of the Federation of Medical Women of Canada. Kevin Chan is Chair of the Acute Care Committee of the Canadian Paediatric Society, and served on the billing/finance committee of the Pediatric Section of the Ontario Medical Association. Catherine Farrell is Chair of the Scientific Steering Committee for the Canadian Paediatric Surveillance Program and member of the Board of Directors of the Canadian Critical Care Society. She has received funding from Health Canada and the Canadian Institutes of Health Research, as well as an honorarium for a presentation at a continuing education conference from the Université de Sherbrooke. Sarah Forgie is the President of the Association of Medical Microbiology and Infectious Disease Canada, and received an honorarium for participation in the Senior Medical Advisory Committee at Ryerson Medical School. Fatima Kakkar has received salary support for protected time from the FRQS Chercheur Boursieurs Program, and received honoraria for presentations given to the Association des Pédiatres du Québec. She has also served on the Quebec COVID-19 maternal-child health advisory committee, and received grants from FRQS Reseau SIDA Maladies Infectieuses and Foundation of Stars. Charlotte Moore Hepburn is the Director of Childrens Mental Health of Ontario, and the Director of medical affairs for the Canadian Paediatric Society and the Canadian Paediatric Surveillance Program. Shaun Morris has received honouraria for lectures from GlaxoSmithKline. He was a member of an ad hoc advisory boards for Pfizer Canada and Sanofi Pasteur. Jesse Papenburg has received consultant fees from Merck, honouraria from Astra-Zeneca and Seegene, and is a voting member of the National Advisory Committee on Immunization. He is also site principal investigator for industry trials by MedImmune, Merck, Astra-Zeneca, and Sanofi, and is Medical Lead of the Study Steering Committee for AbbVie. Rupeena Purewal is a consultant for Verity Pharmaceuticals. Christina Ricci and Marina Salvadori are employees of the Public Health Agency of Canada. Manish Sadarangani has been an investigator on projects, unrelated to the current work, funded by GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. He is also Chair/Deputy Chair of Data Safety Monitoring Boards for two COVID-19 vaccine trials. Karina Top received a grant from GlaxoSmithKline to her institution outside the submitted work. No other competing interests were declared.Clinical Protocols https://cpsp.cps.ca/uploads/studies/COVID-19_Protocol_EN-rev-02-2022.pdf Funding StatementWe gratefully acknowledge the financial support received from the Public Health Agency of Canada to the Canadian Paediatric Surveillance Program, in support of the COVID-19 study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Research Ethics Boards at Health Canada-Public Agency of Canada (REB #2020-002P), the Research Ethics Board at the Hospital for Sick Children (REB #1000070001), the Institutional Review Board at the Centre Hospitalier Universitaire Sainte-Justine (IRB #MP-21-2021-2901), and at individual sites as required by local policies. The Canadian Paediatric Surveillance Program, from which these data were obtained, also operates under the authority derived from Section 4 of the Department of Health Act and Section 3 of the Public Health Agency of Canada act.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data that underlie the results reported in this article (text, tables, figures and appendices) and that abide by the privacy rules of the Canadian Paediatric Surveillance Program and the Public Health Agency of Canada can be made available to investigators whose secondary data analysis study protocol has been approved by an independent research ethics board.